PHP Biotech Announces Participation as Sponsor and Presenter at 2026 Oncology Venture Summit

August 03, 2026

Southlake, Texas - August 03, 2026 -
PHP Biotech, a US-based biotechnology company specializing in therapeutic nanobodies for cancer treatment, announced today its participation as both sponsor and featured presenter at the 3rd Annual Oncology Venture, Innovation & Partnering Summit scheduled for October 19-20, 2026, in Cambridge, Massachusetts.

The summit, organized by Discovery on Target, brings together investors, corporate executives, entrepreneurs, and business leaders in oncology to explore funding opportunities, business development strategies, and innovations in cancer therapeutics and diagnostics. As a sponsor and presenter, the company will contribute to critical discussions on artificial intelligence-enabled oncology, radiopharmaceuticals, China's expanding role in biopharma, and the 2026 investment and partnering outlook.

"Our participation in this premier oncology summit reflects our commitment to advancing cancer therapeutics through innovative nanobody technology," said Robert Gahagen, representing the company. "The summit provides an invaluable platform to share our progress in developing novel therapeutic approaches, particularly our work with p53-targeting nanobodies, while engaging with potential partners and investors who

share our vision for transforming cancer treatment."

The two-day event features networking sessions, panel discussions, fireside chats, and technology showcases designed to facilitate meaningful connections between stakeholders in the oncology ecosystem. Attendees will gain strategic insights from oncology executives and learn about the latest innovations shaping the future of cancer therapeutics.

The company's presentation at the summit comes at a pivotal time in its development trajectory. The biotechnology firm has been advancing its lead candidate, PHP53-nb, a patented nanobody designed to reactivate the functionality of the p53 protein in cancer cells. This first-in-class humanized nanobody demonstrates strong anti-tumor efficacy with low toxicity, offering a novel mechanism of action for treating aggressive cancers such as triple-negative breast cancer.

The summit agenda addresses critical topics including investment opportunities in oncology, perspectives from major pharmaceutical companies on cancer research and development, and the integration of artificial intelligence in drug discovery. These discussions align with the company's focus on leveraging cutting-edge technology to develop next-generation cancer therapeutics.

PHP Biotech specializes in nanobody and translational biotechnology, focusing on developing novel therapeutic nanobodies that target and destroy cancer cells. The company's nanobody platform offers several advantages over traditional monoclonal antibodies, including enhanced cell penetration and the ability to target intracellular proteins previously considered undruggable. The platform supports multiple therapeutic applications beyond the lead program, with a pipeline including additional humanized camelid nanobodies for various cancer indications.

The Oncology Venture, Innovation & Partnering Summit has established itself as a leading forum for oncology innovation, bringing together key decision-makers from across the biotechnology and pharmaceutical industries. The event facilitates strategic partnerships, investment opportunities, and collaborative initiatives aimed at accelerating the development of breakthrough cancer treatments.
###
For more information about PHP Biotech, contact the company here:PHP BiotechRobert Gahagen(888) 739-6972contact@phpbiotech.com550 Reserve St. STE 190?Southlake, TX 76092

PHP Biotech

Our goal: better treatments for aggressive cancers. We developed PHP53-nb?pairing our 3-NAntC p53-reactivating peptide with the GEN01-AD nanobody platform to restore tumor-suppressing function. Promising results in TNBC and pancreatic cancer.

Website: https://phpbiotech.com/

Email: contact@phpbiotech.com

Phone: (888) 739-6972